• by:
  • November 16th, 2022
  • Category: whitepaper

The Value of Quantitative Imaging in COPD Bioequivalence Studies for Biosimilar Development


This white paper explores the value of using quantitative imaging in respiratory clinical trials.

White Paper

The Value of Quantitative Imaging in COPD Bioequivalence Studies for Biosimilar Development

This white paper explores the value of using quantitative imaging in respiratory clinical trials

Quantitative analysis of medical imagingin clinical trials for obstructive respiratory diseases can be very beneficial for biosimilar development. In thisarticle Radiomics explores the uses and benefits of medical imaging in respiratory trials in a whitepaper titled "The Value of Quantitative Imaging in COPD Bioequivalence Studies for Biosimilar Development"


Please fill in your details below and get access to read the full article directly. 

World COPD Day

Quantitative analysis of medical imaging in clinical trials for obstructive respiratory diseases can be very beneficial for biosimilar development. In this article Radiomics explores the uses and benefits of medical imaging in respiratory trials in a whitepaper titled "The Value of Quantitative Imaging in COPD Bioequivalence Studies for Biosimilar Development"


Please fill in your details below and get access to read the full article directly